Recent trials

Trials recently included in TrialResults-center.org RSS


Govindan, 2017
NCT01285609
ipilimumab + chemotherapy vs placebo + chemotherapy
in lung cancer (metastatic)
01/11/2017 00:00:00

immune checkpoint inhibition for lung cancer (metastatic) in all type of patients

KEYNOTE-021 phase 2, 2016
NCT02039674
pembrolizumab + platinum-based CT vs platinum-based CT
in lung cancer (metastatic)
28/10/2017 00:00:00

immune checkpoint inhibition for lung cancer (metastatic) in all type of patients

immune checkpoint inhibition for lung cancer (metastatic) in first line

KEYNOTE-059,
NCT02335411
pembrolizumab vs nil
in gastric or gastro-oesophageal junction cancer (advanced)
24/10/2017 00:00:00

immune checkpoint inhibition for gastric or gastro-oesophageal junction cancer (advanced) in all type of patients

ATTRACTION-2, 2017
NCT02267343
nivolumab vs placebo
in gastric or gastro-oesophageal junction cancer (advanced)
23/10/2017 00:00:00

immune checkpoint inhibition for gastric or gastro-oesophageal junction cancer (advanced) in all type of patients

CABOSUN, 2017
NCT01835158
cabozantinib vs sunitinib
in renal-cell carcinoma (advanced)
21/10/2017 00:00:00

multi target TKI for renal-cell carcinoma (advanced) in all type of patients

durvalumab phase 1/2, durvalumab vs nil
in urothelial carcinoma (advanced)
21/10/2017 00:00:00

immune checkpoint inhibition for urothelial carcinoma (advanced) in all type of patients

ALUR, 2018
NCT02604342
alectinib vs chemotherapy
in lung cancer (metastatic)
09/09/2017 00:00:00

ALK inhibitors for lung cancer (metastatic) in ALK positive patients

CheckMate-214, 2017
NCT02231749
nivolumab + ipilimumab vs sunitinib
in renal-cell carcinoma (advanced)
16/08/2017 00:00:00

immune checkpoint inhibition for renal-cell carcinoma (advanced) in all type of patients

ORIGINE, 2012
NCT00069784
insulin glargine vs control
in diabetes type 2
13/08/2017 00:00:00

glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients

FLAURA, 2017
NCT02296125
osimertinib vs placebo
in lung cancer (metastatic)
04/08/2017 00:00:00

EGFR inhibitors for lung cancer (metastatic) in all type of patients

EGFR inhibitors for lung cancer (metastatic) in first line

SOLO2/ENGOT-Ov21,
NCT01874353
olaparib vs placebo
in ovarian cancer
04/08/2017 00:00:00

poly ADP-ribose polymerase (PARP) inhibitor for ovarian cancer in all type of patient (BRCA mutated or not)

poly ADP-ribose polymerase (PARP) inhibitor for ovarian cancer in patients with BRCA mutation

Checkmate-141, 2016
NCT02105636
nivolumab vs standard treatment
in Head and neck cancer
31/07/2017 00:00:00

immune checkpoint inhibition for Head and neck cancer in all type of patients

KEYNOTE-185, 2018
NCT02579863
pembrolizumab, lenalidomide, dexametahsone vs lenalidomide, dexamethasone
in multiple myeloma
31/07/2017 00:00:00

immune checkpoint inhibition for multiple myeloma in all type of patients

KEYNOTE-183, 2018
NCT02576977
pembrolizumab + pomadoline + dexamethasone vs pomadoline + dexamethasone
in multiple myeloma
31/07/2017 00:00:00

immune checkpoint inhibition for multiple myeloma in all type of patients

KEYNOTE-040,
NCT02252042
pembrolizumab vs standard treatment
in Head and neck cancer
30/07/2017 00:00:00

immune checkpoint inhibition for Head and neck cancer in all type of patients

REVEAL HPS-3 TIMI-55, 2017
NCT01252953
anacetrapib vs placebo
in cardiovascular prevention
01/07/2017 00:00:00

CEPT inhibition for cardiovascular prevention in all type of patients

HDL increasing drugs for cardiovascular prevention in all type of patients

CANTOS, 2017
NCT01327846
canakinumab vs placebo
in post myocardial infarction
01/07/2017 00:00:00

anti inflammatory drugs for post acute coronary syndromes in all type of patients

anti inflammatory drugs for post myocardial infarction in all type of patients

CANTOS, 2017
NCT01327846
canakinumab vs placebo
in post acute coronary syndromes
01/07/2017 00:00:00

anti inflammatory drugs for post acute coronary syndromes in all type of patients

anti inflammatory drugs for post myocardial infarction in all type of patients

ARCHER 1050,
NCT01774721
dacomitinib vs gefitinib
in lung cancer (metastatic)
05/06/2017 00:00:00

EGFR inhibitors for lung cancer (metastatic) in all type of patients

Dickler (CALGB 40503°, 2015Letrozole plus bevacizumab vs letrozole
in advanced breast cancer (metastatic)
19/05/2017 00:00:00

angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients

Hyams,
NCT00454805
cediranib + fulvestrant vs fulvestrant
in advanced breast cancer (metastatic)
19/05/2017 00:00:00

angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients

De Jong, enzastaurin + fulvestrant vs Fulvestrant
in advanced breast cancer (metastatic)
19/05/2017 00:00:00

angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients

LEA, bevacizumab + endocrine therapy vs endocrine therapy
in advanced breast cancer (metastatic)
19/05/2017 00:00:00

angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients

angiogenesis inhibitors for advanced breast cancer (metastatic) in first line therapy

IMvigor210,
NCT02951767
atezolizumab vs nil
in urothelial carcinoma (advanced)
13/05/2017 00:00:00

immune checkpoint inhibition for urothelial carcinoma (advanced) in all type of patients

Aphinity,
NCT01358877
pertuzumab vs placebo
in early breast cancer
05/03/2017 00:00:00

HER2 inhibitors for early breast cancer in HER2 positive patients

IMVIGOR-130 (monotherapy), 0
NCT02807636
atezolizumab vs control
in urothelial carcinoma (advanced)
18/02/2017 00:00:00

immune checkpoint inhibition for urothelial carcinoma (advanced) in all type of patients

KEYNOTE-045, 2017
NCT02256436
pembrolizumab vs chemotherapy
in urothelial carcinoma (advanced)
18/02/2017 00:00:00

immune checkpoint inhibition for urothelial carcinoma (advanced) in all type of patients

EUCLID, 2016
NCT01732822
ticagrelor vs clopidogrel
in peripheral vascular diseases
14/11/2016 00:00:00

antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication

antiplatelets drug for peripheral vascular diseases in all type of patient

EUCLID, 2016
NCT01732822
ticagrelor vs clopidogrel
in cardiovascular prevention
14/11/2016 00:00:00

antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication

antiplatelets drug for peripheral vascular diseases in all type of patient

COMPASS (rivaroxaban alone), 2017
NCT01776424
rivaroxaban vs aspirin
in cardiovascular prevention
05/10/2016 00:00:00

anticoagulant for cardiovascular prevention in all type of patients

anticoagulant for cardiovascular prevention in secondary prevention

direct factor Xa inhibitors for cardiovascular prevention in secondary prevention

direct oral anticoagulant (DAO) for cardiovascular prevention in secondary prevention